X
Table of Contents
X
Table of Contents
Contents
By
Ru Chen
Key Takeaways
In the US market, GLP-1 meds like Ozempic or Wegovy are expensive brand names. You could pay over $1000 a *month* if you don’t have the right insurance. But what about in other countries? India, Brazil, China, and other countries sell GLP-1 for cheaper than $30 a month. Brand protection and patents just don’t reach Ozempic across the rest of the world, triggering a massive price collapse.
Over a billion people worldwide are living with obesity. What is happening to the GLP-1 patents and why are they expiring? Can you buy cheap GLP-1 from international markets? Is it safe? Let’s explore the patent cliff of GLP-1 meds.
A patent cliff refers to the phenomenon of company profits steeply dropping due to legal patents ending, allowing competitors to make significantly cheaper versions.
When a patent expires, China and India are often able to quickly open generic medication access due to resources and demand. Since both countries have high populations, their obesity rates, even if lower than America, can still reach millions and millions of people. This is very relevant considering obesity is one of the main treatment focuses of GLP-1 medications.
Canada and Brazil also often create millions of test cases for public healthcare reimbursement of off-patent anti-obesity meds. Middle and high-income markets are interesting to look at when considering generic meds like generic Ozempic and Wegovy.
Novo Nordisk and Eli Lilly both have many U.S. patents. Novo currently has 49 granted patents that expire after the main compound patent, extending patent protection until 2042 (for Ozempic, Rybelsus, and Wegovy). Meanwhile, Eli Lilly has been granted 16 patents for Mounjaro and Zepbound. The main compound patent for tirzepatide is going to expire in 2036. Plus, this is not to mention all the other patents each company may have for delivery devices, formulations, et cetera.
As you can see, both Novo and Lilly have strong patent protection over their products within the United States. However, what about in other countries? Novo and Lilly patents in countries like China expire sooner than their patents in America or the E.U. For example, the Novo Nordisk patent for semaglutide in China already expired back in March 2026. Even if generic launches are delayed until next year as noted by Bloomberg, 2027, for regulatory reasons, that still means companies within China are poised to create their local competitor generic drugs.
If you have generic, non-name brand medications in the market, it means someone is producing them. Let’s talk about which companies are currently working on generic semaglutide medications around the world.
India has for decades been known as a “pharmacy of the world” as they make potentially life-saving drugs more widely available at much lower costs.
Dr. Reddy’s, Sun Pharma, Cipla, and Biocon are some of the major Indian pharma titans, moving aggressively with both injectable and oral generic semaglutide formulations. It is very possible that India will quickly have inexpensive generic semaglutide, since the Novo India patent for semaglutide expired back in March of 2026.
Analysts predict that in India, the weight loss drugs could plummet by as much as a whopping 90%. Affordable pricing for this apparent “miracle drug” could rapidly grow the Indian semaglutide market to over a billion dollars.
As of July 2026, Dr. Reddyâs has temporarily paused semaglutide Ozempic production after flagging an active pharmaceutical ingredient (API) issue.
According to Reuters, Sun Pharma has been seeking approval to launch their generic Ozempic in different places, succeeding in South Africa.
Ozempic is taking China by storm, and there has even been widespread shortages of semaglutide in China due to the weight loss drug being part of the Ozempic Frenzy.
Over 15 Chinese companies, including Huadong Medicine and United Laboratories, have advanced candidate generics through numerous trials. There has been a temporary delay of launches, expected to last until April of 2027, though the China Novo semaglutide patent did already expire in March of 2026. This delay could help Novo protect its share of the global semaglutide market, but it seems almost inevitable that the prices will drastically lower soon.
The global desire for generic, affordable GLP-1 medications means there is a massive demand. And where there is massive demand, the supply chain needs to meet it. Even the auto-injector pens and glass cartridge demand is going up, not to mention the actual ingredients of GLP-1 meds.
Since there is this known high demand without worries about the demand dropping, pharmaceutical companies and laboratories around the world are investing in the future of semaglutide and tirzepatide, lowering prices eventually everywhere.
In general, there is an expected 30% to 50% drop of the price as generic GLP-1s enter markets. However, when more competitors enter and people become aware of them, the price could even collapse by 80% or 90%. The globalization means that it can become so easy to get semaglutide or tirzapetide from international markets, making it so that the companies of Lilly and Novo cannot truly dodge these price drops.
At the moment, semaglutide can cost around $1,350 a month. Tirzepatide costs around $1,100 a month. Your prescription cost may vary depending on where and when you are getting it. Of course, if you have insurance that works for the prescription, then you could save significant money. With insurance, semaglutide or tirzepatide could cost around $30 a month.
If there is a huge price plummet, it will mainly be the people who cannot afford health insurance who benefit from the change.
You probably have heard already but when Ozempic, Wegovy, and other weight loss drugs first entered the American market, there were widespread shortages. This spiked prices immensely, making it completely unaffordable and turning Ozempic into a sort of luxury drug. It seemed like only people in Hollywood or other wealthy brackets could afford it, and it was very visible that many celebrities lost weight during this period. This gave it an interesting reputation since it was *known* to be extremely effective for treating diabetes and obesity, yet it was so inaccessible.
During the shortage, regulations about GLP-1 drugs were slacker. The FDA allowed pharmacies to create compounded semaglutide to meet the demand.
Nowadays the national shortage is no longer severe. It resolved after around a three year backorder cycle. As such, regulations for compounded semaglutide became stricter, since it no longer became necessary. However, you may need to obtain a new prescription since the old one will no longer be approved by the FDA.
Generic drugs and biosimilar drugs are slightly different. It depends on if a regulatory agency classifies off-patent semaglutide or tirzepatide as a generic (synthetic chemical) or a biosimilar (recombinant protein). The classification differences can result in varying approval speeds and price discount levels.
A few years ago, the FDA had to decide whether to allow the potentially riskier or less effective compounded semaglutide versions on the market during the shortage. They ended up allowing it so that people who medically needed the drugs could obtain their GLP-1 medications. This meant they could receive the various weight loss, kidney, heart, and liver benefits without waiting so long for the national shortage to be fixed.
There will always be gray and black market drugs for everything under the sun. Be very careful to ensure you are getting safe, physician-prescribed semaglutide or tirzepatide.
Private payers and medical tourism are an important topic to talk about when it comes to sourcing medications or healthcare treatments. Medical tourism refers to going to a different country just for a medical treatment, which may be gray market or even illegal. This is very common for both cosmetic and functional surgeries. It is to be expected that globally, semaglutide and tirzepatide copies have been circulating.
As generic brands enter the market, prices will decrease across the board. This usually means that fewer people will engage in medical tourism, since prices will soon become cheaper in th United States.
Brand-name companies obviously will want to counter the patent cliff with strategic defenses. Let’s take a look at what the GLP-1 originators are currently up to as of July 2026.
Novo Nordisk has patents for semaglutide (e.g. Ozempic and Wegovy), while Eli Lilly has the patents for tirzepatide products in America.
Interestingly, Novo Nordisk and Eli Lilly are currently in a rapidly escalating lawsuit over GLP-1 drug marketing. This happens as international pharma companies set up their own generic semaglutide and tirzepatide launches for the future. This has been escalating as of July 2026, and experts expect to hear more news going forward.
Brand-name makers may be launching their own local generic partnerships or authorized generics to capture lower-tier markets before competitors do.
Novo and Lilly may also be shifting their marketing emphasis away from the classic single-agent semaglutide toward protected, higher-efficacy multi-agonists (e.g., tirzepatide, retatrutide, and CagriSema). Watch their public updates for the latest information about each company’s ideas going forward.
Compounding pharmacies can create compounded semaglutide, tirzepatide, and other drugs. However, these custom mixes of drugs are NOT FDA-approved. They are heavily restricted and NOT recommended, especially now that commercial shortages of semaglutide and tirzepatide have calmed down.
It is possible that official generic approvals will shut down unofficial compounding pharmacy markets by providing regulated, ultra-low-cost alternatives. This can be great for consumers since patients who need the drug to treat their medical needs may otherwise feel forced to turn to compounding pharmacies for emergency custom drugs.
Medications, surgeries, and drugs almost always go international. We live in such a globalized society, and the patent cliff is pushing GLP-1s from high-cost therapies to more foundational, accessible ones. It could be lifesavingly good, as millions of people with type 2 diabetes, liver, kidney, and heart conditions are finding current GLP-1 costs too expensive. But what about the safety and efficacy of these generic name drugs? It is always important to check for the approval and safe use of any new medication you are trying, especially those like GLP-1s that need to be taken long-term.
The first decade of GLP-1 has been incredible, yet also incredibly *expensive*. You run into shortages everywhere due to it being such a popular, effective weight loss and diabetes drug. In the next decade, it can be expected that GLP-1 prices will drop and that these medications will be able to help more people around the world.
Ru Chen
Content Writer
Ru Chen is a content writer with several years of experience in creating engaging and well-researched articles. She mostly writes about coffee, business, digital marketing, and law. In her free time, she can be found watching horror movies and playing board games with her partner in Brooklyn.
Ru Chen is a content writer with several years of experience in creating engaging and well-researched articles. She mostly writes about coffee, business, digital marketing, and law. In her free time, she can be found watching horror movies and playing board games with her partner in Brooklyn.
